BTS: India's Ozempic Paradox

For years, a single drug sat behind a patent wall – expensive, scarce and out of reach for most of the world.

And then, almost overnight, that wall collapsed.

A patent expired. Dozens of Indian pharma companies moved in. Factories spun up. Regulators cleared approvals. And within days, Ozempic, one of the most talked-about drugs in the world, was suddenly available in India at a fraction of its American price.

At ₹1,290 a month, finally, a miracle drug for the masses.

But beneath the celebration, something didn’t add up.

Because in a country with over 250 million people living with obesity, only about 200,000 are actually using it.

This is not just a story about Ozempic.

It’s a story about pricing, perception, culture, and the strange gap between availability and reality.

From patent laws and pharma economics to celebrity denial cycles and black-market injections, from American shortages to India’s emerging demand – this episode unpacks what really happens when a “wonder drug” goes generic.

Because abundance isn’t the same as access. And cheap isn’t the same as affordable.

Today, we break down the business, culture, and unintended consequences behind India’s Ozempic moment, and what it reveals about how we think about health, wealth, and the bodies we live in.

The Desi VC Podcast presents BTS, a research-driven, documentary-style series that pulls back the curtain on the systems, incentives, and stories shaping the world around us.